Physician

Alan D Kritz, M.D.

According to 2025 Medicare claims, Alan Kritz, M.D. (NPI: 1508813155) practices hematology/oncology in the Raleigh-Cary, NC market, with the plurality of this provider's patient population coming from Wake, NC. This provider's primary affiliated billing organization is REX HOSPITAL INC (NPI: 1942239538; TIN: 561509260) and primary practice location at 27607-0114. Kritz is affiliated with the CHESS Genesis, LLC (ACO ID: D0237), participating under the REACH model.

Kritz's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 418 traditional Medicare patients, billed 1,231 HCPCS/CPT codes, and received $132,839 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 1,603 prescription claims across 285 beneficiaries totaling $4,996,247 in drug costs, led by Pomalyst (Pomalidomide). DME data shows 23 claims. Open Payments data shows 5 records totaling $631. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $133,111 to $132,839. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $547,981 to $4,996,247. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	527	1,801	$133,111
2016	432	1,171	$86,581
2017	440	1,361	$104,116
2018	446	1,363	$109,323
2019	459	1,389	$116,975
2020	410	1,326	$112,567
2021	392	1,350	$140,276
2022	421	1,292	$137,620
2023	468	1,377	$151,038
2024	418	1,231	$132,839

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	165	897	$547,981
2016	164	881	$880,026
2017	205	1,503	$1,177,162
2018	233	1,738	$1,958,019
2019	249	1,721	$2,856,177
2020	225	1,864	$3,612,129
2021	206	1,225	$2,516,273
2022	214	1,040	$2,743,295
2023	247	1,275	$2,739,856
2024	285	1,603	$4,996,247

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	156	$24,882
2016	N/R	131	$6,046
2017	N/R	184	$30,566
2018	N/R	77	$3,771
2019	N/R	13	$1,825
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	23	$936
2023	N/R	31	$7,446
2024	N/R	23	$602

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	53	53	$155
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	19	19	$129
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	193	675	$125
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	16	29	$85
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	247	379	$82

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Pomalyst	Pomalidomide	37	1,036	$715,551
Lenalidomide	Lenalidomide	43	1,162	$617,008
Revlimid	Lenalidomide	20	560	$464,206
Imbruvica	Ibrutinib	27	756	$430,627
Calquence	Acalabrutinib Maleate	24	720	$340,522

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	11	$376
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	12	$226

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	5	$631	Celgene Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Alan D. Kritz, M.D.?

Tedicare shows public-source Medicare data for Alan D. Kritz, M.D. (NPI 1508813155), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Alan D. Kritz, M.D. have ACO affiliation data?

Alan D. Kritz, M.D. is shown with ACO affiliation data for CHESS Genesis, LLC (REACH, ACO ID D0237).

What billing organization is linked to Alan D. Kritz, M.D.?

Alan D. Kritz, M.D. is linked to REX HOSPITAL INC (billing NPI 1942239538) in the available physician profile data.

Does Alan D. Kritz, M.D. have Open Payments data?

Alan D. Kritz, M.D. has 5 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.